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OBJECTIVE—Two recent genome-wide association (GWA)
studies have revealed novel loci for type 1 diabetes, a common
multifactorial disease with a strong genetic component. To fully
utilize the GWA data that we had obtained by genotyping 563
type 1 diabetes probands and 1,146 control subjects, as well as
483 case subject–parent trios, using the Illumina HumanHap550
BeadChip, we designed a full stage 2 study to capture other
possible association signals.
RESEARCH DESIGN AND METHODS—From our existing
datasets, we selected 982 markers with P  0.05 in both GWA
cohorts. Genotyping these in an independent set of 636 nuclear
families with 974 affected offspring revealed 75 markers that also
had P  0.05 in this third cohort. Among these, six single
nucleotide polymorphisms in ﬁve novel loci also had P  0.05 in
the Wellcome Trust Case-Control Consortium dataset and were
further tested in 1,303 type 1 diabetes probands from the
Diabetes Control and Complications Trial/Epidemiology of Dia-
betes Interventions and Complications (DCCT/EDIC) plus 1,673
control subjects.
RESULTS—Two markers (rs9976767 and rs3757247) remained
signiﬁcant after adjusting for the number of tests in this last
cohort; they reside in UBASH3A (OR 1.16; combined P  2.33 
10
8) and BACH2 (1.13; combined P  1.25  10
6).
CONCLUSIONS—Evaluation of a large number of statistical
GWA candidates in several independent cohorts has revealed
additional loci that are associated with type 1 diabetes. The two
genes at these respective loci, UBASH3A and BACH2, are both
biologically relevant to autoimmunity. Diabetes 58:290–295,
2009
T
ype 1 diabetes is a multifactorial disease with a
strong genetic component that results from au-
toimmune destruction of the pancreatic -cells.
The major type 1 diabetes susceptibility locus,
mapping to the HLA class II genes at 6p21 (1) and
encoding highly polymorphic antigen-presenting proteins,
accounts for almost 50% of the genetic risk for type 1
diabetes (2). Several other loci with more modest effects
are known, but they do not account for the remaining
portion of the risk.
The recent development of high-throughput single nu-
cleotide polymorphism (SNP) genotyping array technolo-
gies has enabled us (3) and others (4) to perform high-
density genome-wide association (GWA) studies in search
of the remaining type 1 diabetes loci. We recently reported
the outcome of our GWA for type 1 diabetes in a large
pediatric type 1 diabetic cohort of European descent (3);
in addition to conﬁrming previously identiﬁed loci, we
observed highly signiﬁcant and replicated association with
KIAA0350 (now renamed CLEC16A [C-type lectin domain
family 16 member A]). Subsequent follow-up of our data
also revealed a locus on 12q13 (5). In parallel and inde-
pendently, the Wellcome Trust Case Control Consortium
(WTCCC) (4) also demonstrated replicated (6) association
to the same linkage disequlibrium blocks at 16p13 and
12q13, along with two additional loci on 12q24 and 18p11.
The results that we have reported thus far were of loci
that achieved statistical signiﬁcance on the basis of the
results of the GWA genotyping (stage 1) or replication in
additional cohorts (stage 2) of only a small number of the
most promising loci. Here, we describe the results of a full
evaluation of all statistical candidates from the GWA
phase.
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Study populations
Type 1 diabetes cohort from Canada. The Canadian cohort consisted of
1,120 nuclear family trios (one affected child and two parents) and 267
independent type 1 diabetes cases, collected in pediatric diabetes clinics in
Montreal, Toronto, Ottawa, and Winnipeg. The median age at onset is 8 years
with lower and upper quartiles at 4.6 and 11 years, respectively. All patients
were diagnosed under the age of 18 years and treated with insulin since
diagnosis, and none have stopped treatment for any reason since. Disease
diagnosis was based on these clinical criteria rather than any laboratory tests.
Ethnic backgrounds were of mixed European descent, with the largest single
subset (409 families) being French Canadian. The Research Ethics Board of
the Montreal Children’s Hospital and other participating centers approved the
study, and written informed consent was obtained from all subjects.
Type 1 Diabetes Genetics Consortium cohort. The Type 1 Diabetes
Genetics Consortium cohort consisted of 549 families (2,350 individuals) with
at least two children diagnosed with diabetes and both parents available as of
the July 2005 data freeze. Criteria were age at diagnosis below 35 years and
uninterrupted treatment with insulin within 6 months of diagnosis. For
siblings of probands diagnosed under the age of 35 years, the age-at-diagnosis
limit was extended to 45 years if they were lean and had positive islet cell
antibodies and/or low C-peptide levels at diagnosis. The median age is 8 years
with quartiles at 4 and 13 years. The samples were collected in Europe, North
America, and Australia.
Type 1 diabetes cohort from Philadelphia. The type 1 diabetes cohort
consisted of 103 children recruited at the Children’s Hospital of Philadelphia
(CHOP) since September 2006, as previously described (3).
Diabetes Control and Complications Trial/Epidemiology of Diabetes
Complications and Interventions type 1 diabetes cohort. The Diabetes
Control and Complications Trial was a multicenter randomized clinical trial to
determine the effect of intensive insulin treatment with respect to reduced
development and progression of retinopathy and nephropathy complications in
patients with type 1 diabetes (7,8). A total of 1,441 subjects with type 1 diabetes
were recruited from 29 centers across North America into the DCCT between
1983 and 1989; they were between 13 and 39 years of age, and 53% were male.
They were recruited into two cohorts: the primary prevention cohort consisted of
726 subjects with no retinopathy, an albumin excretion rate 28 gmin, and
diabetes duration of 1–5 years and was studied to determine whether intensive
therapy prevented the development of diabetic retinopathy in patients with no
retinopathy. The secondary intervention cohort consisted of 715 subjects who
had nonproliferative retinopathy, a urinary albumin excretion rate 140 g/min,
and diabetes duration of 1–15 years and was studied to determine whether
intensive therapy would affect the progression of early retinopathy (7). Approval
for the Diabetes Control and Complications Trial/Epidemiology of Diabetes
Complications and Interventions (DCCT/EDIC) genetics study was provided by
the Research Ethics Board of the Hospital for Sick Children, Toronto.
The Illumina 1M assay was genotyped on all available probands. To detect
and remove outliers due to population stratiﬁcation from the majority of
self-reported white probands, Eigenstrat (9) was used to select probands by
sequential analysis. After exclusions of outliers, there were 1,303 DCCT/EDIC
probands (695 male and 608 female), with mean  SD age of type 1 diabetes
diagnosis 21  8 years (range 0–38).
Control subjects from Philadelphia. The control group used to match with
the DCCT/EDIC cases included 2,024 children with self-reported Caucasian
TABLE 1
Flow process
Sample information Genotyping Statistics*
Stage 1 (GWA)
Case-control cohort 563 type 1 diabetes case
subjects (mean age at
diagnosis 7.6 years
range 0.1–18	) and
1,146 control subjects
550,000 SNPs on the Illumina
HumanHap550
982 SNPs outside the
MHC region with P 
0.05 in the same
direction in both
cohorts
Family cohort 483 type 1 diabetes
case-parent trios
(mean case subject age
of diagnosis 8.1 years
range 0.5–18	)
550,000 SNPs on the Illumina
HumanHap550
Stage 2
Family cohort 636 nuclear type 1
diabetic families (mean
age at diagnosis of
type 1 diabetes case
subjects 9.6 years
[range 0.1–37])
982 SNPs on the Illumina
GoldenGate
75 SNPs with P  0.05 in
the same direction as
the GWA stage
Additional evidence: WTCCC
dataset (ref. 4) 2,000 type 1 diabetes
case and 3,000 control
subjects (age of type 1
diabetes diagnosis 17
years and insulin
dependence since
diagnosis, with a
minimum period of at
least 6 months)
500,000 SNPs on the
Affymetrix GeneChip
33 SNPs with P  0.05 in
the same direction of
the above cohorts; 6
SNPs in ﬁve loci were
from previously
unreported loci
Validation: case-control
cohort† 1,303 DCCT/EDIC type 1
diabetes case subjects
(mean age at diagnosis
21 years range 0–38	)
and 1,673 control
subjects
1 million SNPs on the
Illumina 1M assay; 550,000
SNPs on the Illumina
HumanHap550
Two of the six SNPs with
P  0.01 in the same
direction of the above
cohorts
*Two of the six SNPs, rs10758593 and rs10758594, are in tight linkage disequilibrium (r
2  0.86). Therefore, ﬁve independent hypothesis were
tested, and the corrected signiﬁcant level for multiple comparisons is 
0.01. All P values are two sided. †Six SNPs in ﬁve loci were tested
in the validation cohort. MHC, major histocompatibility complex.
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not have diabetes or a ﬁrst-degree relative with type 1 diabetes. These
individuals were recruited by CHOP’s clinicians and nursing staff within the
CHOP’s health care network, including four primary care clinics and several
group practices and outpatient practices that included routine check-up visits
of healthy children. Of these 2,024 individuals, 1,673 were selected using
population-stratiﬁcation analysis from Eigenstrat similar to that described
above for DCCT/EDIC probands (868 male, 801 female, and 4 with ambiguous
gender). We removed 351 (17.3%) self-reported European individuals from the
control group to address the population heterogeneity. The Research Ethics
Board of CHOP approved the study, and written informed consent was
obtained from all subjects.
Genotyping. Genotypes for this study were obtained using the Inﬁnium and
GoldenGate platforms from Illumina. We performed high-throughput genome-
wide SNP genotyping using the Illumina Inﬁnium II HumanHap550 BeadChip
technology (Illumina, San Diego) (10,11) at the Center for Applied Genomics
at CHOP. We used 750 ng genomic DNA to genotype each sample according
to the manufacturer’s guidelines. DCCT/EDIC samples were genotyped on the
Illumina 1M chip at Illumina (San Diego, CA).
Statistics. All statistical tests for association were carried out using the
software package PLINK (12). The single-marker analysis for the genome-
wide data were carried out using a 
2 test on allele-count differences between
563 case and 1,146 control subjects. Odds ratios (ORs) and corresponding 95%
CIs were calculated for the association analysis. The transmission disequilib-
rium test was used to calculate P values on differences between transmitted
and untransmitted allele counts in the type 1 diabetic trios and nuclear
families. Counts of untransmitted and transmitted alleles from heterozygous
parents to affected offspring were determined using the standard transmission
disequilibrium test implemented in the Haploview software package (13). The
P values from the case-control and family-based analyses in our three
discovery cohorts were combined by weighted z scores to quantify the overall
evidence for association.
RESULTS
The ﬂow process of this study is shown in Table 1.
Comparisons of the statistical power of each population
cohort are shown in supplementary Fig. 1 (available in an
online appendix at http://dx.doi.org/10.2337/db08-1022).
Using our GWA data from 563 Caucasian type 1 diabetes
probands and 1,146 control subjects plus 483 type 1
diabetes case-parent trios using the Illumina Human-
Hap550 BeadChip (3), we identiﬁed 982 SNPs outside the
major histocompatibility complex region that were sugges-
tive of a potential type 1 diabetes association in the same
direction in both cohorts (P  0.05). We then genotyped
these SNPs using the Illumina GoldenGate platform in an
independent cohort of 636 nuclear type 1 diabetic families
from Canada and the Type 1 Diabetes Genetics Consor-
tium. With the completion of genotyping the third cohort,
the WTCCC summary data became available (http://www.
wtccc.org.uk) (4). Consequently, we selected markers that
met the P  0.05 threshold both in this third cohort and in
the WTCCC dataset (4). Imputation from the Affymetrix
TABLE 2
Cohort datasets leveraged in selection of candidate loci for further validation efforts (data sorted by chromosomal position)
Chr SNP Position
Type 1 diabetic families:Montreal
and T1DGC Case-control cohort
Trans:
untrans OR TDT P
Aff allele
frequency
Ctrl allele
frequency P OR
1 rs1983853 85,083,780 202:254 0.8 0.015 0.121 0.151 0.021 0.779
1 rs1230661 113,987,113 456:331 1.378 8.36  10
6 0.267 0.216 8.75  10
4 1.324
1 rs4839335 114,035,394 482:354 1.362 9.56  10
6 0.3 0.25 0.002 1.285
1 rs1217407 114,195,271 505:395 1.278 2.46  10
4 0.298 0.244 7.42  10
4 1.316
1 rs12566340 114,221,851 492:379 1.298 1.29  10
4 0.288 0.237 0.0015 1.299
1 rs7529353 114,221,985 474:354 1.339 3.04  10
5 0.294 0.242 9.75  10
4 1.309
1 rs2358994 114,230,984 398:287 1.387 2.22  10
5 0.232 0.175 7.11  10
5 1.426
1 rs7520320 114,336,816 211:169 1.249 0.031 0.136 0.107 0.013 1.315
1 rs12029644 114,338,303 222:172 1.291 0.012 0.136 0.105 0.008 1.343
2 rs2111485 162,818,782 417:500 0.834 0.0061 0.393 0.433 0.027 0.849
2 rs1990760 162,832,297 422:518 0.815 0.0017 0.398 0.434 0.048 0.864
2 rs1024161 204,429,997 534:462 1.156 0.023 0.439 0.397 0.02 1.191
2 rs926169 204,430,997 521:459 1.135 0.048 0.426 0.38 0.0094 1.212
2 rs231726 204,449,111 502:427 1.176 0.014 0.358 0.321 0.028 1.184
6 rs3757247 91,014,184 545:482 1.13 0.049 0.504 0.455 0.0075 1.216
9 rs10758593 4,282,083 539:462 1.17 0.015 0.492 0.426 2.97  10
4 1.303
9 rs10758594 4,285,583 535:456 1.17 0.012 0.513 0.451 6.66  10
4 1.282
10 rs706779 6,138,830 424:506 0.838 0.0072 0.425 0.492 2.60  10
4 0.764
10 rs3118470 6,141,719 504:431 1.169 0.017 0.365 0.306 4.62  10
4 1.308
10 rs7072793 6,146,272 574:507 1.132 0.042 0.486 0.41 2.96  10
5 1.358
10 rs7073236 6,146,558 566:464 1.22 0.0015 0.487 0.414 5.67  10
5 1.343
11 rs1004446 2,126,719 378:514 0.735 5.27  10
6 0.254 0.354 4.38  10
9 0.622
12 rs11171710 54,654,345 464:574 0.808 6.40  10
4 0.405 0.462 0.0016 0.792
12 rs10876864 54,687,352 631:528 1.195 0.0025 0.458 0.388 8.39  10
5 1.336
12 rs1701704 54,698,754 549:425 1.292 7.09  10
5 0.379 0.303 9.89  10
6 1.402
15 rs8035957 36,625,556 423:342 1.24 0.0034 0.304 0.263 0.011 1.225
16 rs12931878 10,949,695 362:446 0.812 0.0031 0.16 0.225 1.01  10
5 0.657
16 rs1035089 10,955,851 517:451 1.146 0.034 0.48 0.42 8.25  10
4 1.277
16 rs13330041 10,996,309 291:345 0.844 0.032 0.172 0.246 1.01  10
6 0.637
16 rs725613 11,077,184 397:465 0.854 0.021 0.3 0.39 3.24  10
7 0.672
16 rs2041670 11,082,153 384:444 0.865 0.037 0.265 0.345 2.01  10
6 0.682
16 rs17673553 11,149,407 319:387 0.824 0.01 0.202 0.279 1.30  10
6 0.655
21 rs9976767 42,709,459 571:504 1.13 0.041 0.474 0.437 0.038 1.164
Continued on following page
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(supplementary Table 1). As shown in Table 2, 33 markers
met the P  0.05 threshold across all four cohorts.
Although the bulk of them mapped to known loci (PTPN22
[14], 12q13, KIAA0350 [3,6], IL2RA [15–17], CTLA4 [18],
and IFIH1 [19]), six SNPs in ﬁve loci were completely
novel. These were tested in an additional case-control
cohort consisting of 1,303 type 1 diabetes probands from
the DCCT/EDIC study and an independent dataset of 1,673
control subjects from Philadelphia who had been geno-
typed on the Illumina 1M and HumanHap550K BeadChips,
respectively.
Two signals replicated in this ﬁfth independent cohort
(Table 3), and the P values were signiﬁcant after correc-
tion for testing six markers (ﬁve independent loci). They
map to UBASH3A (ubiquitin-associated and SH3 domain-
containing protein A) and BACH2 (broad complex-
tramtrack-bric-a-brac [BTB] and cap ‘n’ collar [CNC]
homology 2). Table 4 shows that rs9976767 is in fact
signiﬁcant at the genome-wide level when all ﬁve cohorts
utilized were combined (P  2.33  10
8).
DISCUSSION
Taken together, our full second-stage approach and com-
bined meta-analysis have revealed additional loci associ-
ated with type 1 diabetes. Clearly the risks are relatively
modest compared with previously described associations,
and it was only with this sample size at our disposal that
we could we detect and establish these signals as true
positives through an independent validation effort.
UBASH3A is the only gene in its corresponding region
of linkage disequilibrium. Mice lacking Sts2 (the mouse
homologue for UBASH3A) have been shown to be normal
in all respects, including T-cell function (20). Mice lacking
both Sts1 and Sts2 do have increased splenocyte numbers
and are hyper-responsive to T-cell receptor stimulation. It
has been suggested that STS1 and STS2 are critical regu-
lators of the signaling pathways that control T-cell activa-
tion (20).
BACH2 is also the only gene at its corresponding region
of linkage disequilibrium. The gene product is a member of
the small Maf family, which consists of basic region
TABLE 2
Continued
Type 1 diabetic family trios
Combined P
WTCCC
Gene
Trans:
untrans OR TDT P
Aff allele
frequency
Ctrl allele
frequency P OR
105:136 0.772 0.046 0.00060 0.122 0.137 0.036 0.878 EDG7*
209:161 1.298 0.013 7.56  10
10 0.276 0.217 3.34  10
11 1.371 PTPN22
224:172 1.302 0.009 9.5  10
10 0.299 0.241 2.81  10
10 1.339 PTPN22
225:168 1.339 0.004 1.89  10
9 0.298 0.240 1.70  10
10 1.344 PTPN22
212:164 1.293 0.013 2.08  10
8 0.287 0.226 1.09  10
11 1.377 PTPN22
218:165 1.321 0.0068 7.88  10
10 0.287 0.227 2.69  10
11 1.368 PTPN22
181:127 1.425 0.0021 1.95  10
10 0.246 0.179 4.05  10
16 1.504 PTPN22
124:82 1.512 0.0034 1.55  10
5 0.134 0.115 0.0042 1.195 PTPN22
120:80 1.5 0.0047 5.54  10
6 0.130 0.109 0.0018 1.218 PTPN22
210:254 0.827 0.041 3.76  10
5 0.359 0.395 0.00034 0.858 IFIH1
203:251 0.809 0.024 4.48  10
5 0.350 0.389 8.73  10
5 0.845 IFIH1
222:173 1.283 0.014 0.000175 0.441 0.403 0.00024 1.166 CTLA4
236:191 1.236 0.029 0.000349 0.440 0.402 0.00022 1.167 CTLA4
228:177 1.288 0.011 0.000105 0.372 0.332 5.10  10
5 1.191 CTLA4
253:209 1.211 0.041 0.00035 0.511 0.489 0.033 1.092 BACH2*
254:209 1.215 0.037 7.14  10
6 0.440 0.410 0.004 1.129 GLIS3*
253:209 1.211 0.041 1.60  10
5 0.456 0.427 0.004 1.127 GLIS3*
185:257 0.72 6.16  10
4 9.33  10
8 0.419 0.458 0.00012 0.852 IL2RA
240:181 1.326 0.004 1.27  10
6 0.361 0.319 1.32  10
5 1.208 IL2RA
268:200 1.34 0.0017 2.45  10
7 0.455 0.409 6.24  10
6 1.207 IL2RA
264:196 1.347 0.0015 5.89  10
9 0.455 0.409 7.31  10
6 1.205 IL2RA
160:228 0.7018 5.56  10
4 2.61  10
16 0.443 0.464 0.047 0.921 INS
197:244 0.807 0.025 3.20  10
7 0.404 0.452 2.40  10
6 0.821 12q13
265:188 1.41 2.97  10
4 4.56  10
9 0.475 0.414 2.04  10
9 1.283 12q13
245:180 1.361 0.0016 2.78  10
10 0.397 0.339 5.91  10
9 1.282 12q13
204:162 1.259 0.028 2.88  10
5 0.292 0.268 0.01 1.126 RASGRP1*
128:162 0.79 0.046 1.51  10
8 0.158 0.178 0.0088 0.865 KIAA0350
265:212 1.25 0.015 9.85  10
7 0.482 0.439 2.59  10
5 1.190 KIAA0350
145:183 0.792 0.036 1.45  10
8 0.175 0.204 0.00028 0.825 KIAA0350
178:248 0.718 6.95  10
4 1.67  10
11 0.292 0.340 3.90  10
7 0.797 KIAA0350
172:233 0.738 0.0024 7.08  10
10 0.264 0.315 7.05  10
8 0.781 KIAA0350
146:203 0.719 0.0023 3.82  10
10 0.217 0.249 0.00031 0.838 KIAA0350
260:203 1.281 0.008 0.00020 0.493 0.461 0.002 1.135 UBASH3A*
The six SNPs indicated in bold type represent novel associations deemed appropriate for further investigation. For the joint analysis of the
three discovery cohorts, the two family cohorts were pooled for the TDT analysis. The TDT results were combined with those of the
case-control cohort by weighted z scores. Combined P values for the three cohorts are shown, together with the gene in which the markers
resides or to which they are nearest. P values are two sided in each instance. *Gene not previously implicated in type 1 diabetes. Aff allele
freq, minor allele frequency in affected individuals; Chr, chromosome; Ctrl allele freq, minor allele frequency in unaffected individuals;
T1DGC, Type 1 Diabetes Genetics Consortium; Trans:untrans, transmitted:untransmitted allele ratio.
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tional activators or repressors depending on the proteins
with which they heterodimerize. Muto et al. (21) found
that Bach2
/ mice had relatively high levels of serum IgM
but low levels of IgA and IgG subclasses. The Bach2
/
mice have also been reported to present with deﬁcient
T-cell–independent and T-cell–dependent IgG responses,
leading the authors to conclude that BACH2 was a regu-
lator of the antibody response.
It should also be noted that rs1983853 yielded a nomi-
nally signiﬁcant association with type 1 diabetes in all of
the cohorts but did not survive correction for multiple
testing in the ﬁnal validation attempt in the Toronto
dataset. This SNP resides in endothelial differentiation
gene 7 (EDG7; formerly LPA3), which has been implicated
in mechanisms of embryo implantation (22). The SNPs on
GLIS3 and RASGRP1 were not validated. They may have
been false positives in the earlier stages; alternatively, lack
of replication in DCCT/EDIC may be due to different
and/or weaker genetic risk determinants in this cohort
with late age of onset of type 1 diabetes. This question
must be addressed in future studies. The GLI-similar 3
(GLIS3) gene plays important roles in the development of
pancreatic -cells. Mutations in this gene cause a rare
syndrome with neonatal diabetes and congenital hypothy-
roidism (23). The RAS guanyl releasing protein 1 (RAS-
GRP1) gene has important roles in immune regulation, and
it has been suggested that it contributes to the autoimmu-
nity of systemic lupus erythematosus (24).
In addition to our ﬁndings, what we failed to ﬁnd
deserves comment. In addition to the ﬁndings described
above, our study conﬁrmed another interesting locus,
rs17696736 (C12orf30) at 12q24, reported in the WTCCC
study (4,6). Our GWA family cohort suggested type 1
diabetes association with P  0.011; however, limited by
the sample size, our GWA case-control cohort did not
show statistical signiﬁcance (P  0.05). To validate the
type 1 diabetes association, we genotyped rs17696736
using the Sequenom iPLEX assay (Sequenom, Cambridge,
MA) in the 1,120 Canadian families and the 549 Type 1
Diabetes Genetics Consortium families. The call rate of
rs17696736 genotyping was 99.8%, and no Mendelian error
was found. With the family-based association test (25), we
conﬁrmed the type 1 diabetes association with P  8.00 
10
7, minor G allele frequency 0.452, and OR 1.276.
However, given the very thorough coverage of European
genetic variation by the Hap550 and the power of our
aggregate sample size, it is very unlikely that we missed
more than a very small number of common variants with
an effect size approaching that of the INS (minor allele
frequency 0.2 and OR 0.5; each of our three discovery
cohorts has 99.9% power to detect it at 
0.05 level) or
PTPN22 (minor allele frequency 0.1 and OR 1.8; each of
our three discovery cohorts has 99.0% power to detect it
at 
0.05 level) loci.
Undoubtedly, larger sample sizes and meta-analysis of
all available GWA data will discover an increasing number
of loci with decreasing effect sizes, which are unlikely to
explain the remaining familial clustering of type 1 diabe-
tes. Such explanation should be sought, it appears, in rare
variants, the detection of which is now coming within
reach with the use of high-throughput methods for se-
quencing and for detecting structural variation.
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TABLE 3
Validation results for the six SNPs of interest selected from the discovery process in the DCCT/EDIC type 1 diabetes probands and
CHOP control subjects
Chr SNP Position Gene Aff allele freq Ctrl allele freq OR (95% CI) P
1 rs1983853 85,083,780 EDG7 0.132 0.153 0.842 (0.726–0.976) 0.022
6 rs3757247 91,014,184 BACH2 0.497 0.463 1.144 (1.033–1.268) 0.010
9 rs10758593 4,282,083 GLIS3 0.429 0.426 1.013 (0.913–1.124) 0.81
9 rs10758594 4,285,583 GLIS3 0.434 0.443 0.963 (0.869–1.068) 0.48
15 rs8035957 36,625,556 RASGRP1 0.270 0.261 1.047 (0.932–1.176) 0.44
21 rs9976767 42,709,459 UBASH3A 0.474 0.436 1.165 (1.051–1.292) 0.0036
The two SNPs that successfully replicated are presented in bold type. Minor allele frequencies, P values, and ORs are shown together with
the gene in which the markers resides or to which they are nearest. P values are two-sided in each instance. Aff allele freq, allele frequency
in affected individuals; Chr, chromosome; Ctrl allele freq, allele frequency in unaffected individuals.
TABLE 4
Meta-analysis of the ﬁve cohorts
Chr SNP Position Gene Allele OR (95% CI) P
1 rs1983853 85,083,780 EDG7 A 0.833 (0.773–0.898) 1.87  10
6
6 rs3757247 91,014,184 BACH2 A 1.134 (1.078–1.193) 1.25  10
6
9 rs10758593 4,282,083 GLIS3 A 1.131 (1.074–1.190) 2.64  10
6
9 rs10758594 4,285,583 GLIS3 A 1.114 (1.058–1.172) 3.51  10
5
15 rs8035957 36,625,556 RASGRP1 C 1.144 (1.080–1.211) 3.92  10
6
21 rs9976767 42,709,459 UBASH3A C 1.155 (1.098–1.215) 2.33  10
8
P values and ORs are shown together with the relevant allele for each of the six SNPs.
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